Skin vasodilator effect of exogenous urotensin-II in hypertensives not exposed to antihypertensive medication

Blood Pressure

Volumn 17, Issue 1, 2008, Pages 18-25

  Rossi, Marco ^a   Magagna, Armando ^a   Di Maria, Cinzia ^a   Franzoni, Ferdinando ^a   Taddei, Stefano ^a   Santoro, Gino ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Essential arterial hypertension; Iontophoresis; L NMMA; Laser Doppler flowmetry; Skin blood flowmotion; Skin vascular tone; Urotensin II

Indexed keywords

ANTIHYPERTENSIVE AGENT; N(G) METHYLARGININE; UROTENSIN II;

ADULT; ARTICLE; BLOOD VESSEL TONE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG MECHANISM; DRUG RESPONSE; ENDOTHELIUM; ESSENTIAL HYPERTENSION; FEMALE; FOREARM; FOURIER ANALYSIS; HUMAN; IONTOPHORESIS; LASER DOPPLER FLOWMETRY; MALE; PRIORITY JOURNAL; SKIN BLOOD FLOW; SKIN BLOOD VESSEL; VASODILATATION;

ADMINISTRATION, CUTANEOUS; ADULT; BLOOD FLOW VELOCITY; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; INJECTIONS, INTRADERMAL; IONTOPHORESIS; LASER-DOPPLER FLOWMETRY; MALE; MIDDLE AGED; OMEGA-N-METHYLARGININE; REFERENCE VALUES; SKIN; UROTENSINS; VASODILATOR AGENTS;

EID: 45949096565     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08037050701757994     Document Type: Article

References (25)

1. Ames, R. S., Sarau, H. M., Chambers, J. K., Willette, R. N., Aiyar, N. V. Romanic, A. M. et al. (1999) Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature, 401, pp. 282-286.
2. Gardiner, S. M., March, J. E., Kemp, P. A., Davenport, A. P. and Bennett, T. (2001) Depressor and regionally selective vasodilator effects of human and rat urotensin-II in conscious rats. Br J Pharmacol, 132, pp. 1625-1629.
3. Hillier, C., Berry, C., Petrie, M. C., Hamilton, C., Brown, A. and McMurray, J. J. V. (2001) Effect of urotensin-II in human arteries and veins of varying caliber. Circulation, 103, pp. 1378-1381.
4. Camarda, V., Rizzi, A., Calo, G., Gendron, G., Perron, S. I. Kostenis, E. et al. (2002) Effect of human urotensin-II in isolated vessels of various species; Comparison with other vasoactive agents. Naunyn Schmiedebergs Arch Pharmacol, 36, pp. 141-149.
5. Douglas, S. A., Sulpizio, A. C., Piercy, V., Sarau, H. M., Ames, R. S. Aiyar, N. V. et al. (2002) Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol, 131, pp. 1262-1274.
6. Bohm, F. and Pernown, J. (2002) Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol, 135, pp. 25-27.
7. Stirrat, A., Gallagher, M., Douglas, S. A., Ohlstein, E. H., Berry, C. Kirk, A. et al. (2001) Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol, 280, pp. 925-928.
8. Leslie, S. J., Denvir, M. and Webb, D. J. (2000) Human urotensin-II causes vasoconstriction in the human skin microcirculation. Circulation, 102, p. II.
9. Lim, M., Honisett, S., Sparkes, C. D., Komesaroff, P., Kompa, A. and Krum, H. (2004) Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation, 109, pp. 1212-1214.
10. Katugampola, S. D., Maguire, J. J., Kuc, R. E., Wiley, K. E. and Davenport, A. P. (2002) Discovery of recently adopted orphan receptors for apelin, urotensin II, and ghrelin identified using novel radioligands and functional role in the human cardiovascular system. Can J Physiol Pharmacol, 80, pp. 369-374.
11. Ong, K. L., Lam, K. S. and Cheung, B. M. (2005) Urotensin II: Its function in health and its role in disease. Cardiovasc Drugs Ther, 19, pp. 65-75.
12. Cheung, B. M. Y., Leung, R., Man, B. Y. and Wong, L. Y. F. (2004) Plasma concentration of urotensin-II is raised in hypertension. J Hypertens, 22, pp. 1341-1344.
13. Matsushida, M., Shichiri, M., Imai, T., Iwashina, M., Tanaka, H. Takasu, N. et al. (2001) Co-expression of urotensin and its receptor (GPR 14) in human cardiovascular and renal tissues. J Hypertens, 19, pp. 2185-2190.
14. Gilbert, R. E., Douglas, S. A. and Krum, H. (2004) Urotensin-II as novel therapeutic target in the clinical management of cardiorenal disease. Curr Opin Investig Drugs, 3, pp. 276-282.
15. Sondermeijer, B., Kompa, A., Komesaroff, P. and Krum, H. (2005) Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension. Am J Hyper, 18, pp. 1195-1199.
16. Rossi, M., Maurizio, S. and Carpi, A. (2005) Skin blood flowmotion response to insulin iontophoresis in normal subjects. Microvascular Research, 70, pp. 17-20.
17. Rossi, M., Carpi, A., Di Maria, C., Galetta, F. and Santoro, G. (2007) Skin microcirculatory effect of exogenous calcitonin gene-related peptide (CGRP) evaluated by laser Doppler flowmetry coupled with iontophoresis in healthy subjects. Microvasc Res, 73, pp. 124-130.
18. Kvernmo, H. D., Stefanovska, A., Kirkeboen, K. A. and Kvernebo, K. (1999) Oscillations in the human cutaneous blood perfusion signal modified by endothelium-dependent and endothelium-independent vasodilators. Microvasc Res, 57, pp. 298-309.
19. Stefanovska, A., Bracic, M. and Kvernmo, K. (1999) Wavelet analysis of oscillations in the peripheral blood circulation measured by laser Doppler technique. IEEE Trans Biomed Eng, 46, pp. 1230-1239.
20. Colantuoni, A., Bertuglia, S. and Intaglietta, M. (1984) Quantitation of rhythmic diameter changes in arterial microcirculation. Am J Physiol, 246, pp. H508-H517.
21. Colantuoni, A., Bertuglia, S. and Intaglietta, M. (1994) Microvascular vasomotion: Origin of laser Doppler fluxmotion. Int J Microcirc Clin Exp, 14, pp. 151-158.
22. Rossi, M., Taddei, S., Fabbri, A., Tintori, G., Credidio, L. Virdis, A. et al. (1997) Cutaneous vasodilation to acetylcholine in patients with essential hypertension. J Cardiovasc Pharmacol, 29, pp. 406-411.
23. Taddei, S., Virdis, A., Mattei, P. and Salvetti, A. (1993) Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension, 21, pp. 929-933.
24. Taddei, S., Ghiadoni, L., Virdis, A., Buralli, S. and Salvetti, A. (1999) Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired nitric oxide availability in essential hypertensive patients. Circulation, 100, pp. 1400-1405.
25. Taddei, S., Versari, D., Cipriano, A., Ghiadoni, L., Galetta, F. Franzoni, F. et al. (2006) Identification of a cytochrome P450 2C9 derived EDHF in essential hypertensive patients. J Am Coll Cardiol, 48, pp. 508-515.